Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

par pharmaceutical, inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 7 mg - memantine hydrochloride extended-release capsules are indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride extended-release capsules are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride extended-release capsules in pregnant women. adverse developmental effects (decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride extended-release capsules [see data ]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 10 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer's type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. pregnancy category b there are no adequate and well-controlled studies of memantine in pregnant women. memantine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [mrhd] on a mg/m2 basis). slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine beginning pre-mati

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bryant ranch prepack - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride tablets, usp are indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. there are no adequate and well-controlled studies of memantine in pregnant women. memantine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [mrhd] on a mg/m2 basis). slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine beginning pre-mating and continuin

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 15 mg (equivalent: memantine, qty 12.46 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Izraelis - anglų - Ministry of Health

teva pharmaceutical industries ltd, israel - memantine hydrochloride - tablets - memantine hydrochloride 10 mg - memantine - memantine - treatment of patient with moderate to severe alzheimer's disease.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - memantine hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - memantine hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 20 mg (equivalent: memantine, qty 16.62 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; purified talc; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 10 mg (equivalent: memantine, qty 8.31 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 5 mg (equivalent: memantine, qty 4.15 mg) - tablet, film coated - excipient ingredients: purified talc; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).